Table 2.
Clinical predictors of advanced NASH and advanced fibrosis
| Variables | Predictors of advanced NASH (NAS >4) |
Predictors of advanced fibrosis (METAVIR >2) |
||
|---|---|---|---|---|
| Odds ratio (95% CI) |
Odds ratio (95% CI) |
|||
| Univariate | Multivariate | Univariate | Multivariate | |
| Age >median (47 years) | 0.98 (0.59–1.63) | – | 2.30 (1.18–4.63) | 2.01 (1.00–4.15) |
| Gender (female) | 1.86 (1.10–3.15) | 1.76 (1.01–3.10) | 1.82 (0.94–3.53) | – |
| BMI (obese; ≥30 kg/m2) | 2.44 (1.38–4.46) | 2.21 (1.23–4.08) | 1.14 (0.57–2.34) | – |
| ALT (>40 IU/L) | 0.95 (0.45–1.94) | – | 0.95 (0.41–2.49) | – |
| AST (>40 IU/L) | 2.03 (1.21–3.46) | 2.00 (1.14–3.55) | 2.72 (1.36–5.76) | 1.79 (0.83–4.01) |
| ALT/AST < 1 | 1.72 (0.79–3.73) | – | 2.31 (0.94–5.35) | – |
| APRI >1 | 1.70 (0.76–3.76) | – | 5.45 (2.35–12.61) | 3.85 (1.55–9.59) |
ALT = alanine aminotransferase, APRI = AST-to-platelet ratio index, AST = aspartate aminotransferase, BMI = body mass index, NAS = non-alcoholic fatty liver disease (NAFLD) activity score.